- Home
- » Tags
- » Infigratinib
Top View
- 2021 ASCO Direct Highlights at South Carolina Oncology Society Annual Conference: Gastroesophageal, Pancreatic, Hepatobiliary
- Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
- Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer
- Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions
- FGF401 and Vinorelbine Synergistically Mediate Antitumor
- BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, Or Amplified Squamous Cell Carcinoma of the Head and Neck
- Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
- Recurrent Glioblastoma: from Molecular Landscape to New Treatment Perspectives
- FGFR-Selective Tyrosine Kinase Inhibitors, Such As Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Re
- Molecular Pathways and Targeted Therapy in Cholangiocarcinoma
- Oncology Update
- Anti-Tumor Activity of Infigratinib, a Potent and Selective Inhibitor Of
- Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
- Highlights from ASCO-GI 2021 from EORTC Gastrointestinal Tract Cancer Group ✉ Thibaud Koessler 1,2,3 , Maria Alsina3,4, Dirk Arnold3,5, Irit Ben-Aharon3,6, Manfred P
- List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
- FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
- Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
- Infigratinib Offers Second-Line Option for FGFR2-Positive Cholangiocarcinoma by Mark L
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Draft PDCO Agenda 18-21 May 2021
- Low-Dose Infigratinib Treatment Does Not Lead to Changes in Phosphorus in Preclinical Animal Studies
- Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
- Announced That the US Food and Drug Administration
- Phase 2 Study of Lenvatinib Monotherapy As Second-Line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results
- Specialty Pipeline Monthly Update June 2021
- FGF Signaling Regulates Development by Processes Beyond Canonical Pathways
- Foundationone®Cdx Technical Information
- Acquired On-Target Clinical Resistance Validates FGFR4 As a Driver of Hepatocellular Carcinoma
- The Role of Fibroblast Growth Factor Receptor (FGFR)
- The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
- Touchoncology Touchexpert
- Fibroblast Growth Factor Receptor (FGFR)
- Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
- Acquired On-Target Clinical Resistance Validates FGFR4 As a Driver of Hepatocellular Carcinoma
- Therapeutic Implications of Fibroblast Growth Factor Receptor Inhibitors in a Combination Regimen for Solid Tumors (Review)
- Specialty Pipeline MONTHLY UPDATE
- Comprehensive Functional Evaluation of Variants of Fibroblast Growth Factor
- Prior Authorization Criteria
- Infigratinib Versus Gemcitabine Plus Cisplatin As First-Line Therapy In
- Tyrosine Kinase Receptors in Oncology
- Infigratinib) Capsules, for Oral Use Cutaneous Calcinosis, Non-Uremic Calciphylaxis, Vascular Calcification, and Initial U.S